2023-11-14-世界卫生组织-5._Influenza_B_Yamagata_Lineage_-_Egg-derived_-_Southern_Hemisphere_2024_2页_203kb
报告摘要
Influenza B Yamagata Lineage Candidate Vaccine Viruses for 2024 Southern Hemisphere Season
Core Content Overview
This document outlines the candidate vaccine viruses (CVVs) selected for the development and production of influenza vaccines for the 2024 southern hemisphere season, specifically focusing on the B Yamagata lineage. These viruses are derived from eggs and have undergone antigenic and genetic analysis by the WHO Collaborating Centres (WHO CCs) within the Global Influenza Surveillance and Response System (GISRS). All listed CVVs have passed the two-way hemagglutination inhibition (HI) test, ensuring their suitability for vaccine development.
The vaccine composition and formulation are approved by national or regional control authorities. The CVVs and reference antigens (Ref Ags) are available from various institutions, including WHO CCs, CDC, MHRA, NYMC, and others.
Candidate Vaccine Viruses (CVVs)
| Parent Virus | Candidate Vaccine Virus | Type of Virus | Developing Institute | Available From |
|---|---|---|---|---|
| B/Phuket/3073/2013 | Wild type virus | Classical | WHO CCs | MHRA, UK |
| B/California/12/2015 | Wild type virus | Classical | CDC, USA | NYMC, USA |
| B/Brisbane/9/2014 | Wild type virus | Classical | WHO CCs | MHRA, UK |
| B/Utah/09/2014 | Wild type virus | Classical | CDC, USA | MHRA, UK |
| B/Arizona/10/2015 | BX-63 | Classical | NYMC | MHRA, UK |
| B/Arizona/10/2015 | BX-63A | Classical | NYMC | MHRA, UK |
| B/Hong Kong/3417/2014 | Wild type virus | Classical | WHO CCs | NYMC, USA |
| B/Hong Kong/3417/2014 | BX-57 | Classical | NYMC | MHRA, UK |
Reference Antigens (Ref Ags)
| Parent Virus | Candidate Vaccine Virus | Egg or Cell | Ref Ag Lot Number | Unitage (μg HA/ml) | Available From |
|---|---|---|---|---|---|
| B/Phuket/3073/2013 | Wild type | Egg | B(y)-Ag-2112 | 60 | CBER/FDA, USA |
| B/Phuket/3073/2013 | Wild type | Egg | 21/136 | 66 | MHRA, UK |
| B/Phuket/3073/2013 | Wild type | Egg | 2023BYA | 56 | NIID, Japan |
| B/Phuket/3073/2013 | Wild type | Egg | 2023BYB | 58 | NIID, Japan |
| B/Phuket/3073/2013 | Wild type | Egg | 2017/115B | 85 | TGA, Australia |
| BVR-1B | Wild type | Egg | 2020/136B | 86 | TGA, Australia |
| BVR-1B | Wild type | Egg | 2023/142B | 88 | TGA, Australia |
Sheep Antisera
| Parent Virus | Egg or Cell | Order Lot Number | Available From |
|---|---|---|---|
| B/Phuket/3073/2013 | Egg | B(y)-Ab-2215 | CBER/FDA, USA |
| B/Phuket/3073/2013 | Egg | 19/322 | MHRA, UK |
| B/Phuket/3073/2013 | Egg | 2021BY-1 | NIID, Japan |
| B/Phuket/3073/2013 | Egg | AS425* | TGA, Australia |
| B/Phuket/3073/2013 | Egg | AS426 | TGA, Australia |
| B/Phuket/3073/2013 | Egg | AS449 | TGA, Australia |
New reagent shown in blue
Contact Information
Candidate Vaccine Virus Institutes:
- CCDC: whocc-china@cnic.org.cn
- CDC: pdx1@cdc.gov (Subject: CVV request)
- FCI: whocc@crick.ac.uk
- MHRA: standards@nibsc.org or enquiries@nibsc.org
- NIID: flu-vaccine@.nih.go.jp
- NYMC: doris_bucher@nymc.edu
- VIDRL: whoflu@influenzacentre.org
- WHO CCs and ERLs: [GISRS Collaborating Centres](http://www.who.int/influenza/gisrs laboratory/collaborating centres)
ERLs for Reagents:
- CBER: CBERshippingrequests@fda.hhs.gov
- MHRA: standards@nibsc.org or enquiries@nibsc.org
- NIID: flu-vaccine@.nih.go.jp
- TGA: influenza.reagents@health.gov.au
Additional Information
- The potency testing reagents are developed with support from manufacturers and calibrated by WHO Essential Regulatory Laboratories (ERLs).
- For other CVVs and reagents, refer to the WHO GISRS website.
- For general enquiries, contact: gisrs-whohq@who.int.
试读结束，高清完整版pdf/doc/ppt,请点下载
